Raxone (idebenone) is a man-made drug similar to the naturally occurring antioxidant coenzyme Q10. It is currently under development by Santhera Pharmaceuticals. Because coenzyme Q10 is an antioxidant dietary supplement thought to play a major role in cell survival, researchers are investigating whether idebenone can protect against the brain and spinal cord damage that leads to worsening disability in primary progressive multiple sclerosis (PPMS) patients.

Idebenone was initially developed to treat Alzheimer’s disease and other cognitive defects.

There are two ongoing Phase 2 studies (NCT01854359 and NCT00950248) currently evaluating idebenone’s safety, effectiveness, and mechanism of action as a primary progressive multiple sclerosis treatment. The studies will likely be completed by August 2018.

Positive results have already been published regarding the effects of ibedenone on the respiratory function of patients with Duchenne muscular dystrophy.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

 

  1. http://www.nationalmssociety.org/About-the-Society/News/MS-Trial-Alert-Drug-Study-at-NIH-Recruiting-Pe-(1)
  2. https://mssociety.ca/en/pdf/NAEP-WorkingForMe.pdf
  3. http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(15)60025-3.pdf